SMC accepts apixaban (Eliquis®) for prevention of stroke and systemic embolism in adults with AF

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted apixaban (Eliquis®) for use within NHS Scotland for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ?75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class ?II).   The Detailed Advice accompanying the recommendation (see link below) summarises the evidence on efficacy and safety, the clinical effectiveness issues and the health economic evidence considered by the SMC. This notes that apixaban was superior to standard oral anticoagulation (dose-adjusted warfarin) at preventing stroke or systemic embolism in one large, double-blind study in patients with AF and at least one risk factor for stroke. It was also associated with a significant reduction in risk of major bleeding.
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news